度普利尤单抗治疗儿童特应性皮炎的研究进展  

Dupilumab in the treatment of childhood atopic dermatitis

作　　者：田晶[1] 梁源[1] 马琳[1] Tian Jing;Liang Yuan;Ma Lin(Department of Dermatology,Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,China,Beijing 100045,China)

机构地区：[1]国家儿童医学中心、首都医科大学附属北京儿童医院皮肤科,北京100045

出　　处：《中华皮肤科杂志》2024年第12期1157-1160,共4页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81673042);北京市儿科学科协同发展中心“儿科专项”(XTZD20180502)。

摘　　要：目前一般规律使用保湿剂联合外用糖皮质激素/钙调磷酸酶抑制剂治疗儿童特应性皮炎(AD),部分中重度难治性患儿,需系统用糖皮质激素或超说明书使用其他免疫调节剂,然而这些治疗存在一定的局限性及不良反应。近年来,随着AD关键炎症因子的发现,针对白细胞介素4/13的生物制剂——度普利尤单抗广泛应用于临床并取得一定的效果。本文综述近年来度普利尤单抗治疗儿童AD的临床研究。Currently,childhood atopic dermatitis(AD)is mainly treated by regular use of moisturisers in combination with topical glucocorticoids or calcineurin inhibitors.For some children with refractory moderate-to-severe AD,systemic glucocorticoids or off-label use of other immunomodulators may be required;however,these treatments usually have some limitations and adverse effects.In recent years,with the discovery of key inflammatory factors in AD,dupilumab,a biological agent targeting interleukin-4/13,has been widely used in clinical practice,and shown certain efficacy.This review summarizes recent clinical studies on dupilumab in the treatment of AD in children.

关 键 词：皮炎 特应性 儿童 治疗 生物制剂 度普利尤单抗 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]